

**Amendments to the Claims:**

Please cancel claims 20 and 29, and add new claims 37-40 as indicated below.

1. (previously presented) A conjugate comprising an antibody Fab' fragment, covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least 20 kD, wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

2-24. (canceled)

25. (previously presented) The conjugate of Claim 1 wherein the PEG molecule is covalently attached to the hinge region of the antibody fragment.

26. (previously presented) The conjugate of Claim 1 wherein the antibody fragment comprises an antigen binding site that binds to human interleukin-8 (IL-8).

27. (canceled)

28. (original) The conjugate of Claim 26 wherein the antibody fragment comprising the anti-human IL-8 antigen binding site is humanized.

29. (original) The conjugate of Claim 28 wherein the anti-human IL-8 antigen binding site comprises the complementarity determining region of a light chain polypeptide amino acid sequence selected from the group consisting of the 6G4V11N35A light chain polypeptide amino acid sequence of Fig. 36 (SEQ ID NO: 56) and the 6G4V11N35E light chain polypeptide amino acid sequence of Fig. 45 (SEQ ID NO: 62).

30. (canceled)

31. (original) A composition comprising the conjugate of Claim 1 and a carrier.

32. (original) The composition of Claim 31 that is sterile.

33. (original) The conjugate of Claim 1, wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment and nonproteinaceous polymer molecules that form the conjugate.

34. (original) The conjugate of Claim 1, wherein the covalent structure of the conjugate incorporates one or more nonproteinaceous labels, and wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment, nonproteinaceous polymer and nonproteinaceous label molecules that form the conjugate.

35. (original) The conjugate of Claim 34 wherein at least one nonproteinaceous label is radiolabel.

36. (previously presented) A conjugate comprising a Fab' fragment, attached to a single polyethylene glycol (PEG) molecule of at least 20 kD, wherein said conjugate has an apparent size of at least about 500 kD and at least about 8 fold greater than the apparent size of the antibody fragment.

37. (New) A conjugate comprising an antibody Fab' fragment, covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least about 40 kD, wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

38. (New) A conjugate comprising a humanized antibody Fab' fragment comprising an antigen binding site that binds to human interleukin-8 (IL-8), wherein the anti-human IL-8 antigen binding site comprises the complementarity

determining region of a light chain polypeptide amino acid sequence selected from the group consisting of the 6G4V11N35A light chain polypeptide amino acid sequence of Fig. 36 (SEQ ID NO: 56) and the 6G4V11N35E light chain polypeptide amino acid sequence of Fig. 45 (SEQ ID NO: 62), said humanized antibody Fab' antibody fragment being covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least 20 kD, wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

39. (New) A composition comprising the conjugate of Claim 37 and a carrier.
40. (New) The composition of Claim 39 that is sterile.
41. (New) A composition comprising the conjugate of Claim 38 and a carrier.
42. (New) The composition of Claim 41 that is sterile.